Well, CytoDyn management is nothing if not consistent...as in consistently fumbling the ball on the 1 yard line. If the share price doesn't rise significantly today, the only thing that seems like it will move the needle is FDA approval (or in some other country which will start to generate revenue for CytoDyn).

I don't know of any legal reason why "efficacy" could not have been used, as this report was specifically about the efficacy of the product versus placebo.

Very frustrating, as per usual.